MX2017013875A - Ciertos inhibidores de la proteína quinasa. - Google Patents

Ciertos inhibidores de la proteína quinasa.

Info

Publication number
MX2017013875A
MX2017013875A MX2017013875A MX2017013875A MX2017013875A MX 2017013875 A MX2017013875 A MX 2017013875A MX 2017013875 A MX2017013875 A MX 2017013875A MX 2017013875 A MX2017013875 A MX 2017013875A MX 2017013875 A MX2017013875 A MX 2017013875A
Authority
MX
Mexico
Prior art keywords
protein kinase
kinase inhibitor
certain protein
certain
inhibitors
Prior art date
Application number
MX2017013875A
Other languages
English (en)
Inventor
Weibo Wang
Yang Lijun
Li Tongshuang
Zhao Xingdong
Tan Haohan
Wang Xianlong
Liu Qihong
Jiang Lihua
Liu Yanxin
Lin Min
Sun Jing
Chen Zhifang
LINGHU Li
Chen Ling
Rong Yue
Tan Rui
Zhou Zuwen
Liu Bin
Original Assignee
Chongqing Fochon Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57198165&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017013875(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chongqing Fochon Pharmaceutical Co Ltd filed Critical Chongqing Fochon Pharmaceutical Co Ltd
Publication of MX2017013875A publication Critical patent/MX2017013875A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Se proporcionan aquí ciertos inhibidores de la CDK4/6, composiciones farmacéuticas de los mismos, y métodos para usarlos.
MX2017013875A 2015-04-28 2016-04-28 Ciertos inhibidores de la proteína quinasa. MX2017013875A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562154082P 2015-04-28 2015-04-28
PCT/CN2016/080475 WO2016173505A1 (en) 2015-04-28 2016-04-28 Certain protein kinase inhibitor

Publications (1)

Publication Number Publication Date
MX2017013875A true MX2017013875A (es) 2018-06-22

Family

ID=57198165

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017013875A MX2017013875A (es) 2015-04-28 2016-04-28 Ciertos inhibidores de la proteína quinasa.

Country Status (10)

Country Link
US (1) US10450316B2 (es)
EP (1) EP3288931B2 (es)
CN (1) CN107849012B (es)
BR (1) BR112017023225A2 (es)
DK (1) DK3288931T4 (es)
ES (1) ES2766498T5 (es)
MX (1) MX2017013875A (es)
RU (1) RU2732952C2 (es)
TW (1) TWI696617B (es)
WO (1) WO2016173505A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20170268A1 (es) 2014-06-19 2017-04-21 Ariad Pharma Inc Compuestos de heteroarilo para la inhibicion de cinasa
CN106608879A (zh) 2015-10-27 2017-05-03 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
WO2018113771A1 (en) 2016-12-22 2018-06-28 Betta Pharmaceuticals Co., Ltd Benzimidazole derivatives, preparation methods and uses theirof
CN108794452B (zh) 2017-05-05 2021-05-28 上海时莱生物技术有限公司 具有激酶抑制活性的化合物、其制备方法和用途
JP7233743B2 (ja) * 2017-08-11 2023-03-07 晟科薬業（江蘇）有限公司 プロテインキナーゼ阻害剤としての１ｈ－ピラゾロ［４，３－ｈ］キナゾリン系化合物
TW201920141A (zh) * 2017-08-15 2019-06-01 中國大陸商北京軒義醫藥科技有限公司 Cdk4/6抑制劑及其用途
SG11202012858QA (en) * 2018-06-21 2021-02-25 Betta Pharmaceuticals Co Ltd Crystal form of compound for inhibiting the activity of cdk4/6 and use thereof
CN117222411A (zh) * 2021-03-24 2023-12-12 贝达药业股份有限公司 药物组合、包含其的试剂盒及其用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1470124T3 (da) * 2002-01-22 2006-04-18 Warner Lambert Co 2-(Pyridin-2-yl amino)-pyrido[2,3]pyrimidin-7-oner
US8101625B2 (en) 2005-10-21 2012-01-24 Exelixis, Inc. Pyrimidinones as Casein Kinase II (CK2) modulators
KR20080110912A (ko) 2006-04-19 2008-12-19 노파르티스 아게 인다졸 화합물 및 ｃｄｃ７의 억제 방법
CA2734802C (en) * 2008-08-22 2016-05-31 Novartis Ag Pyrrolopyrimidine compounds as cdk inhibitors
JO2885B1 (en) * 2008-12-22 2015-03-15 ايلي ليلي اند كومباني Protein kinase inhibitors
WO2010098487A1 (en) * 2009-02-26 2010-09-02 Eisai R&D Management Co., Ltd. Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors
CN105189481A (zh) * 2013-03-13 2015-12-23 艾伯维公司 吡啶cdk9激酶抑制剂
GB201321728D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321730D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321729D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
JP6263269B2 (ja) * 2013-12-31 2018-01-17 シュエンジュウ・ファーマ・カンパニー・リミテッド キナーゼ阻害剤及びその使用
CN104910137B (zh) 2014-03-10 2017-04-19 山东轩竹医药科技有限公司 Cdk激酶抑制剂
EP3191469B1 (en) 2014-07-24 2021-12-15 Beta Pharma, Inc. 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof
UY36630A (es) 2015-04-17 2016-11-30 Abbvie Inc Moduladores tricíclicos de la señalización por tnf
CN105153119B (zh) 2015-09-11 2019-01-01 广州必贝特医药技术有限公司 吡啶嘧啶胺类化合物或吡啶吡啶胺类化合物及其应用
CN106608879A (zh) * 2015-10-27 2017-05-03 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
RU2680777C1 (ru) * 2018-02-14 2019-02-26 Сергей Викторович Яблочко Направляющий аппарат центробежного многоступенчатого насоса

Also Published As

Publication number Publication date
RU2017141077A (ru) 2019-05-28
RU2017141077A3 (es) 2019-08-14
EP3288931B2 (en) 2022-07-20
DK3288931T4 (da) 2022-10-24
CN107849012A (zh) 2018-03-27
EP3288931A4 (en) 2018-10-10
WO2016173505A1 (en) 2016-11-03
TWI696617B (zh) 2020-06-21
US20180291027A1 (en) 2018-10-11
EP3288931A1 (en) 2018-03-07
EP3288931B1 (en) 2019-11-06
DK3288931T3 (da) 2020-02-03
BR112017023225A2 (pt) 2018-08-07
ES2766498T3 (es) 2020-06-12
RU2732952C2 (ru) 2020-09-24
CN107849012B (zh) 2021-05-25
ES2766498T5 (es) 2022-11-18
US10450316B2 (en) 2019-10-22
TW201713645A (zh) 2017-04-16

Similar Documents

Publication Publication Date Title
PH12020550622A1 (en) Kras g12c inhibitors
MX2022004304A (es) Agentes inductores de apoptosis.
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
MX2018013983A (es) Inhibidores g12c de kras.
PH12018501151A1 (en) Tank-binding kinase inhibitor compounds
PH12018500907A1 (en) Inhibitors of ret
GEP20217234B (en) Pyridopyrimdinone cdk2/4/6 inhibitors
PH12017500509A1 (en) Benzyl substituted indazoles as bub1 inhibitors
MX2017013875A (es) Ciertos inhibidores de la proteína quinasa.
MX2019001125A (es) Inhibidores de cinasa macrociclica.
EP3293177A4 (en) Tyrosine kinase inhibitor and pharmaceutical composition comprising same
MX2016015862A (es) Compuestos inhibidores de la cinasa de union a tank.
PH12015502041B1 (en) Heteroaryl compounds and uses thereof
MX2020005213A (es) Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.
MX2019007243A (es) Inhibidores de ectonucleotidasa y metodos de uso de los mismos.
NZ725917A (en) Novel polymerase-i inhibitors, uses and methods for making them
MX2018016057A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
EP3359159A4 (en) PHARMACEUTICAL SALTS, PHYSICAL FORMS, AND COMPOSITIONS OF PYRROLOPYRIMIDINE INHIBITORS OF KINASES, AND METHODS OF PREPARATION THEREOF
SA519410093B1 (ar) مركبات بيريميدو بيريميدينون مفيدة كمثبطات دبليو إى إى-1 كيناز
MX2020010116A (es) Compuestos macrociclicos como inhibidores de quinasas del receptor de tropomiosina (trk).
EP3347462A4 (en) METHOD, COMPOSITIONS AND USE OF NOVEL FYN KINASEINHIBITORS
IL264593A (en) Medicinal preparations containing akt protein kinase inhibitors
PH12018500504A1 (en) Compounds useful for inhibiting ror-gamma-t
MX2018013573A (es) Ciertos inhibidores de la proteína cinasa.
MX2019005294A (es) Inhibidores de las interacciones de mtor-deptor y metodos de uso de los mismos.